publication date: Jul. 19, 2019

Funding Opportunities

Leukemia & Lymphoma Society partners with two Australian organizations

The Snowdome Foundation and Leukaemia Foundation joined with the Leukemia & Lymphoma Society to fund four blood cancer research projects with Australian researchers through the LLS Translational Research Program.

The Translational Research Program is an LLS initiative. However, this is the first time two Australian organizations have partnered with LLS to bring funding to Australian researchers.

The four Australian researchers will each receive grants worth $600,000 to extend vital blood cancer research programs across myeloma, lymphoma and leukemia.

The Leukemia & Lymphoma Society-Snowdome Foundation-Leukaemia Foundation Translational Research Program 2018-19 recipients and their respective research proposals are:

Ricky Johnstone,
University of Melbourne;

Stephen Nutt,
Walter and Eliza Hall Institute;

Ashwin Unnikrishnan, University of New South Wales, who each will receive a three-year grant;

Charles Mullighan, St Jude’s Children’s Research Hospital.

Johnstone aims to advance novel precision medicine therapies for diffuse large B-cell lymphoma. He is testing therapies that inhibit a gene called TET2 that is often mutated in blood cancers, including DLBCL. TET2 plays a role in a mechanism called epigenetics, which switches genes on and off. When these epigenetic changes activate or inactivate genes improperly it allows cancer cells to proliferate.

Nutt employs a novel approach to identify and test drugs that can inhibit IRF4 and block the growth of multiple myeloma cells.

Unnikrishnan investigates mechanisms by which azacitidine inhibits myelodysplastic syndrome cells and identify cellular pathways and features that are modulated by azacitidine treatment. This study will provide insight into why some patients do not respond and lay the groundwork for development of alternative therapeutic … Continue reading Leukemia & Lymphoma Society partners with two Australian organizations

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.